These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6430252)

  • 1. Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.
    Wilson AP; Prouse PJ; Gumpel JM
    Ann Rheum Dis; 1984 Jun; 43(3):511-2. PubMed ID: 6430252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteinuria in gold-treated rheumatoid arthritis.
    Katz WA; Blodgett RC; Pietrusko RG
    Ann Intern Med; 1984 Aug; 101(2):176-9. PubMed ID: 6430141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable gold dermatitis and proteinuria: retreatment with auranofin.
    Tosi S; Cagnoli M; Guidi G; Murelli M; Messina K; Colombo B
    Int J Clin Pharmacol Res; 1985; 5(4):265-8. PubMed ID: 2932399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria and oral gold treatment.
    Gonzales JJ; Bohrer MS; Edelson JT; Fendrick AM; Morrison MF
    Ann Intern Med; 1985 Apr; 102(4):561-2. PubMed ID: 3919633
    [No Abstract]   [Full Text] [Related]  

  • 5. Membranous glomerulonephritis as a complication of oral gold therapy.
    Plaza JJ; Herrero G; Barat A; Loutaif JJ; Hernando L; Vallado P; Oliva H
    Ann Intern Med; 1982 Oct; 97(4):563-4. PubMed ID: 6812474
    [No Abstract]   [Full Text] [Related]  

  • 6. Failure of sodium aurothiomalate and triethyl phosphine gold to cause renal tubular injury in rheumatoid arthritis: implications for the aetiology of gold-related nephropathy.
    Crisp AJ; Coughlan RJ; Clark B; Mackintosh D; Panayi GS; Sweny P; Hopper J; Varghese Z
    Clin Rheumatol; 1983 Sep; 2(3):273-6. PubMed ID: 6432404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auranofin (SK + F 39162) induced enterocolitis in rheumatoid arthritis. A case report.
    Jarner D; Nielsen AM
    Scand J Rheumatol; 1983; 12(3):254-6. PubMed ID: 6414080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary results of oral gold treatment with auranofin following lack of success of intramuscular gold therapy].
    Rainer F; Ulreich A
    Wien Klin Wochenschr Suppl; 1984; 156():49-51. PubMed ID: 6442058
    [No Abstract]   [Full Text] [Related]  

  • 9. Auranofin: experience to date.
    Blodgett RC
    Am J Med; 1983 Dec; 75(6A):86-9. PubMed ID: 6419601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-month comparative trial of auranofin and D-penicillamine in rheumatoid arthritis.
    Felix-Davies DD; Stewart AM; Wilkinson BR; Bateman JR; Delamere JP
    Am J Med; 1983 Dec; 75(6A):138-41. PubMed ID: 6419596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin versus penicillamine in rheumatoid arthritis. One-year results from a prospective clinical investigation.
    Manthorpe R; Hørbov S; Sylvest J; Vinterberg H
    Scand J Rheumatol; 1986; 15(1):13-22. PubMed ID: 3083505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety and efficacy of auranofin and parenteral gold compounds: a review.
    Horton RJ
    Scand J Rheumatol Suppl; 1983; 51():100-10. PubMed ID: 6426044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term tolerance of oral gold therapy in rheumatoid arthritis. Frequency and intensity of undesirable side effects].
    Goebel KM; Storck U
    Schweiz Med Wochenschr; 1985 Dec; 115(49):1775-7. PubMed ID: 3937234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single blind study.
    van Riel PL; van de Putte LB; Gribnau FW; Macrae KD
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():51-6. PubMed ID: 6432414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.
    Chaffman M; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1984 May; 27(5):378-424. PubMed ID: 6426923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worldwide clinical experience with auranofin.
    Morris RW; Cole DS; Horton J; Heuer MA; Pietrusko RG
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():105-11. PubMed ID: 6432408
    [No Abstract]   [Full Text] [Related]  

  • 17. [Auranofin. Mechanism of action, pharmacokinetics and clinical use. Comparison with injectable gold salts].
    Chamouard JM; Clerc D; Bisson M; Medicis P; Massias P
    Rev Rhum Mal Osteoartic; 1985 Apr; 52(4):277-82. PubMed ID: 3923604
    [No Abstract]   [Full Text] [Related]  

  • 18. Auranofin: dose-related risk to benefit.
    Weiss TE
    Am J Med; 1983 Dec; 75(6A):128-32. PubMed ID: 6419594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of worldwide safety experience with auranofin.
    Heuer MA; Pietrusko RG; Morris RW; Scheffler BJ
    J Rheumatol; 1985 Aug; 12(4):695-9. PubMed ID: 3932651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of rheumatoid arthritis with the oral gold preparation Auranofin].
    Trnavský K; Zbojanová M
    Cas Lek Cesk; 1982 Nov; 122(45):1382-4. PubMed ID: 6821244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.